Bill Sponsor
Senate Bill 1873
117th Congress(2021-2022)
Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Introduced
Introduced
Introduced in Senate on May 27, 2021
Overview
Text
Sponsor
Introduced
May 27, 2021
Latest Action
May 27, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1873
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
Idaho
Democrat
Arizona
Republican
Arkansas
Democrat
California
Democrat
Delaware
Democrat
Delaware
Democrat
Georgia
Republican
Indiana
Republican
Indiana
Republican
Louisiana
Republican
Louisiana
Democrat
Maryland
Democrat
Michigan
Democrat
Minnesota
Democrat
Minnesota
Republican
Mississippi
Republican
Mississippi
Republican
Missouri
Democrat
Montana
Republican
Nebraska
Democrat
New Hampshire
Democrat
New Hampshire
Democrat
New Jersey
Democrat
New Mexico
Republican
North Carolina
Republican
North Carolina
Republican
North Dakota
Democrat
Pennsylvania
Democrat
Rhode Island
Democrat
Rhode Island
Republican
South Carolina
Republican
South Dakota
Democrat
Wisconsin
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021

This bill provides for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types. The Government Accountability Office must report on the resulting utilization and effectiveness of such tests.

Text (1)
Actions (2)
05/27/2021
Read twice and referred to the Committee on Finance.
05/27/2021
Introduced in Senate
Public Record
Record Updated
Mar 8, 2023 8:12:35 PM